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Part I 
NITROGbN MUSTARD 
AS A TREALl1ENT FOR 
Canine Malignant Lymphoma 
Elroy C. Jemsen, D.V.M. 
Since 1942 the beta-chlorethyl amines 
(nitrogen mustards) have been used in 
the treatment of neoplastic diseases of the 
lymphoid and hemopoietic systems. Al-
pert, et all, reports in human medicine, 
that this drug has been used to retard 
such diseases as: Hodgkin's Disease, 
chronic leukemias, poycythemia vera, 
lympho-sarcoma, transitional cell carcino-
mas and in certain undifferentiated car-
cinomas of the lung and testis. Remission 
in symptoms and reduction in size of tum-
or masses have been achieved in a signi-
ficant number of patients suffering from 
these diseases. 
The pharmacological activity of this 
drug as reported by Gilman and Philips2, 
is that this substance has a potent cyto-
toxic effect on actively proliferating cells, 
the precise nature of which is still only 
partially known. Cellular metabolic 
changes which occur are: a reduction in 
oxygen consumption, depression of aero-
bic and anareobic glycolysis, inhibition of 
mitotic activity and inactivation of some 
enzyme systems. They further report that 
sublethal doses in animals causes the 
lymphoid tissue to undergo fragmentation 
and atrophy. The bone marrow suffers 
depletion of the hemopoietic cells and the 
mucosa of the gastrointestinal tract un-
dergoes necrosis and desquamation. 
Dr. Jensen is an Instructor in the Department 
of Medicine and Surgery, Iowa State College. 
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Bader3 reports the use of nitrogen mus-
tard on a 3-year-old female Cocker Spa-
niel suffering from a malignant lympho-
sarcoma. The dog showed regression of 
the lymph nodes after two days of treat-
ment. There was no relapse 70 days after 
.. treatment although he remarks that this 
is likely to occur. Moss and Jourdan4 re-
port the use of nitrogen mustard on four 
dogs. Two were suffering lymphosarcoma, 
one from a mast cell sarcoma and another 
from a lymphadenitis. They stated that 
in the advanced cases of lymphosarcoma 
and the mast cell sarcoma, that the use of 
nitrogen mustard was of little value. The 
dog suffering from lymphosarcoma, one 
from a mast cell sarcoma and another 
from a lymphadenitis. They stated that 
in the advanced cases of lymphosarcoma 
and the mast cell sarcoma, that the use 
of nitrogen mustard was of little value. 
The dog suffering from lymphadenitis 
(purulent) was definitely benefited by 
the treatment. These authors also state 
that their results indicated that some dogs 
showed susceptibility to infection due to 
reduced resistance following treatment. 
Except for these two articles, very little 
has been reported of the use of nitrogen 
mustard in the veterinary literature. 
The purpose of this work was to clini-
cally evaluate the efficacy of this drug as 
a treatment for malignant lymphoma in 
the dog. 
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Pathology 
Primary neoplasms of the canine 
lymph nodes are nearly always malignant. 
Some confusion exists as to terminology 
of this type of neoplasm as they have been 
designated as lymphoma, lymphosarcoma 
lymphoblastoma, lymphocytoma, lympha-
denosis, lymphomatosis, leukemia and 
pseudoleukemia. Bloom5 states that "the 
term malignant lymphoma is the most ap-
propriate, since it suitably defines the en-
tire group of primary lymphoid tumors 
which can be further subdivided into sev-
eral main subgroups, depending on the 
structural and clinical characteristics." 
Bloom and MeyerG report that malig-
nant lymphoma with multiple lymph node 
envolvement is more common in occurr-
ence than those involving only a solitary 
or regional lymph node. In a group of 
10,000 dogs studied by these author~, they 
report a total of 20 cases of malIgnant 
lymphoma or 0.2 percent. They also 
found that the age range for this neo-
plasm was· 5-12 years with an average of 
9.08 years. In their study they found 
there was a breed incidence of the follow-
ing. Scottish Terrier 7, Boston Terrier, 
Cocker Spaniel, and Chow Chow 2 each, 
and the Wire Haired Fox Terrier and 
German Shepherd 1 each. From this 
study it would indicate that the disease is 
more likely to occur in the above men-
tioned breeds. 
The etiology of the disease is unknown. 
The course of the malady is usually 3-4 
months although the condition may last 
1-3 years. Probably one of the first sym-
ptoms noticed by the owner is an enlarge-
ment of the superficial lymph nodes. Most 
frequently, the owner notices enlarge-
ment of the throat and neck region (man-
dibular and cervical) lymph nodes. If the 
owner is not very observant, these early 
swellings may go unnoticed,· especially 
in a long haired dog. Often the first 
symptoms that the client notes is a res-
piratory distress caused by enlargement 
of the bronchial and mediastinal lymph 
nodes. Prior to these manifestations, the 
dog may have appeared relatively nor-
mal. Later the dog becomes less active 
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and weak which is partially attributed to 
the anemia which usually becomes a part 
of the disease syndrome. Occasional vom-
iting may be noted as well as diarrhea and 
anorexia. Some exhibit polydyspia and 
polyuria. Coughing and respiratory e~­
barrassment occurs if the lymph nodes m 
the region of the lungs are greatly en-
larged. The temperature usually remains 
normal although slight elevations may be 
observed. During the terminal stage the 
animal becomes cachectic due to the pro-
fuse diarrhea, anorexia and anemia. Pur-
ulent nasal and ocular discharges are usu-
ally noted. 
Hematological studies usually indicate 
a non-specific leukocytosis which is due 
to the increased number of segmented and 
non-segmented neutrophils. Rarely is 
there a true leukemia blood picture as 
found in the human. An anemia is usual-
ly always present at least during the ter-
minal stage. 
Histologically, the neoplastic cells may 
be of lymphocytic, lymphoblastic, lymp-
osarcoma or mixed cell types. This neo-
plastic tissue may not only be found in the 
lymph nodes, liver and spleen, but ~ay 
also involve such organs as the tonSIls, 
prostate, bone marrow, lungs, adrenals, 
pancreas and others. 
A positive diagnosis can not b~ m~de 
solely on the basis of a blood exammatIOn. 
The only positive method for diagnosis 
is a biopsy from one of the enlarged su-
perficial lymph nodes and sectioning for 
histiological studies. 
Materials and Methods 
Nitrogen mustard was administered 
intravenously at a dosage varying from 
0.1-.5 mg.jkg. Under no circumstances 
should the dosage exceed 0.8 mg./kg. 
daily. The product used was Mustargen *, 
a trade-name of Merck and Company for 
Mechlorethamine hydrochloride. There 
are 10 mg. of nitrogen mustard in each 
sterile vial triturated with 90 mg. of anhy-
drous sodium chloride. We like to add 
10 cc. of sterile distilled water to this so 
as to have 1.0 mg. of nitrogen mustard 
per cc. of diluent. A new vial must. be 
used each day. Due to its irritant actIOn, 
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all necessary precautions must be taken 
when administering the drug. Rubber 
gloves are suggested for the handling of 
the syringes as blistering may occur if 
any of the drug should come in contact 
with the skin. A syringe filled with a 
clear fluid such as sterile normal saline 
should be used for the initial venipunc-
ture in order to be sure that the needle 
is well in the vein. The medication can 
also be given by injecting the material in-
to the rubber tubing of a running intra-
venous infusion set with a 25 gauge need-
le. Weisberger, et aF, advise the admin-
istration of L-cysteine prior to the inject-
ion of nitrogen mustards as it has a tend-
ency to decrease and modify the severe 
leukopenia. Likewise, L-cysteine causes 
a reduction in the incidence of nausea and 
vomiting which occurs as a sequale to 
the injection of nitrogen mustard. Their 
results seemed to indicate that there is a 
selective effect on the granulocytes with-
out any appreciable protection for the 
malignant cells. Brandt and Griffins ob-
served that this effect is specific to L-cy-
steine as their related compounds show 
no activity. Their experimentation with 
rats and mice revealed that when L-cys-
teine was given 5--45 minutes prior to 
the injection of nitrogen mustard, it pro-
tected them against 6-8 times the normal 
dose. The dosage of L-cysteine adminis-
tered in five of the six cases used in this 
report was 1-2 mg.jkg. diluted in 10 cc. of 
sterile distilled water. 
Case # 1 
The patient was a 4-year-old, spayed, 
27 pound, female Cocker Spaniel showing 
a swelling of all palpable lymph nodes, a 
bilaterial ulcerative keratitis and slight 
anemia. The duration of the illness was 
about 1% weeks. The activity of the dog 
was normal. A biopsy was taken from the 
right popliteal lymph node and diag-
nosed as malignant lymphoma upon mi-
Hemoglobin 
Red Blood Cells 
White Blood Cells 
Stabs 
Segments 
Monocytes 
Lymphocytes 
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76.7% or 11.12 Gm. 
5,970,000 
20,680 
9,600 
7,000 
500 
4,000 
croscopic examination. Blood studies re-
vealed the following: 
Nitrogen mustard was administered for 
four consecutive days at the rate of 0.1 
mg.jkg. daily. Eighteen milligrams of L-
cysteine was given intravenously pri:r to 
the introduction of the nitrogen mustard. 
One Livitamin (Massengill) was given 
daily during and after the course of treat-
ment. At the end of the 4 days treatment, 
there was considerable decrease in the 
size of the superficial lymph nodes. The 
following day after cessation of treatment, 
220 cc. of whole blood was given intra-
venously to counteract the anemia. The 
dog was discharged 2 days later. The 
owner reported that the lymph nodes be-
gan enlarging 2 days after discharge. She 
stated that the dog was very depressed, 
wanting to lie around most of the time. 
She had the dog put to sleep by the ani-
mal rescue league three weeks after dis-
charge. 
Case # 2 
This was a 28 pound, 9-year-old, male, 
Cocker Spaniel which was brought to the 
clinic to have tisthroat checked for a sus-
pected foreign body as it had a marked 
dyspnea and considerable coughing. All 
of the superficial lymph nodes were in-
creased in size. Oxygen was administered 
to the dog for a few hours to allay the 
marked dyspnea. A blood examination 
3 days prior to medication revealed the 
following: 
Hemoglobin 59.1 '/r 
Red Blood Cells 
White Blood Cells 
Stabs 
Segments 
Lymphocytes 
Sedimentation rate 57 mm/hr. 
or 8.57 Gm. 
5,145,000 
32,240 
1,400 
4,400 
26,400 
No L-cysteine was given in this case. 
The daily dosage of nitrogen mustard was 
0.1 mg.jkg. or a total of 1.27 mg. During 
treatment the dog was given two Livita-
min capsules daily. 
* A portion of the Mustargen used in this 
study was supplied for investigational use by 
Merck & Co., Inc., Rahway, N. J. 
The second half of Dr. Jensen's article will 
appear in the next issue of the I.S.C. Veterinar-
ian. 
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